Pre-Test Relapsing Ovarian Cancer: Expert Advice for Selecting New and Emerging Targeted Therapeutics Pre-Test Which of the following statements regarding ovarian cancer is TRUE? The overall 5-year relative survival rate of invasive epithelial ovarian cancer is 39% Ovarian cancer is the 2nd most deadly cancer among women Ovarian cancer relapses in more than 70% of patients Ovarian cancer most often occurs in women aged 50-54 Unsure Mirvetuximab soravtansine targets which of the following in cancer treatment? Epidermal growth factor receptor (EGFR) Folate receptor alpha (FOLR1) Human epidermal growth factor receptor 2 (HER2) Poly (ADP-ribose) polymerase (PARP) Unsure Tumor treating fields (TTFields) affect which of the following structures as part of its mechanism of action in cancer therapy? Cytoplasmic tubulin Lysosome membranes Intracellular receptor complexes Extracellular receptor complexes Unsure Which of the following should occur before and during treatment with mirvetuximab soravtansine? Colonoscopy Intravenous magnesium administration Ophthalmic exam Premedication with an antipyretic Unsure How often do you employ a shared decision-making approach when developing ovarian cancer treatment plans that considers patient goals and treatment tolerability? Always Often Sometimes Rarely Never
